Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTS-201
- Development stage
- Preclinical
- Lead developer
- METiS Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MTS-201 is an investigational small molecule therapeutic being developed by Metis Pharmaceuticals for the treatment of metabolic and gastrointestinal diseases, including obesity, type 2 diabetes (T2D), metabolic-associated steatohepatitis (MASH), and short bowel syndrome (SBS). Currently in the IND-enabling phase, MTS-201 is part of a pipeline that utilizes Metis's proprietary AI-driven platforms to optimize drug discovery and delivery. While the specific mechanism of action and biological target remain undisclosed, the drug's broad indication profile suggests it may modulate pathways involved in glucose homeostasis, lipid metabolism, and intestinal epithelial growth.
Beyond the preview
Go deeper on MTS-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MTS-201.